| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Carles Pericay | Q38545623 |
| P2093 | author name string | Fernando Rivera | |
| Carlos Gomez-Martin | |||
| Esteban Rodrigo Imedio | |||
| Alejo Cassinello | |||
| Inmaculada Nuñez | |||
| P2860 | cites work | Chemotherapy for advanced gastric cancer | Q24236634 |
| Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials | Q26764802 | ||
| Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease | Q27027061 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer | Q28082921 | ||
| Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 | ||
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer | Q33341957 | ||
| Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction | Q33380002 | ||
| The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial | Q33405235 | ||
| The role of chemotherapy in metastatic gastric cancer. | Q34220901 | ||
| Medical management of gastric cancer: a 2014 update | Q34326546 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie | Q34594956 | ||
| Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. | Q34603290 | ||
| Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial | Q34616772 | ||
| Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis | Q34655369 | ||
| Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34656353 | ||
| Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestiv | Q34665199 | ||
| Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies | Q35288940 | ||
| Advanced gastric cancer: is there enough evidence to call second-line therapy standard? | Q36429808 | ||
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Q36892840 | ||
| Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? | Q36964966 | ||
| Diverse eastern and Western approaches to the management of gastric cancer. | Q37141671 | ||
| Management of advanced gastric cancer. | Q37989161 | ||
| Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials | Q38034487 | ||
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 | ||
| Geographic differences in approach to advanced gastric cancer: Is there a standard approach? | Q38114265 | ||
| Optimal chemotherapy for advanced gastric cancer: is there a global consensus? | Q38139297 | ||
| Clinical Trials and Approval of Anti-cancer Agents | Q38427205 | ||
| Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer | Q40347623 | ||
| Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02. | Q41608289 | ||
| Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 | ||
| Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel | Q43056329 | ||
| A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy | Q43164688 | ||
| Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression | Q44734913 | ||
| Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 | ||
| Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie | Q46694609 | ||
| Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 | ||
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. | Q53610419 | ||
| Optimal indications for second-line chemotherapy in advanced gastric cancer | Q83194207 | ||
| Management of gastric cancer | Q85267974 | ||
| Not only chemotherapy in the second-line treatment of metastatic gastric cancer | Q87195636 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| stomach neoplasm | Q4335552 | ||
| gastroesophageal junction adenocarcinoma | Q18556563 | ||
| esophageal neoplasm | Q56014520 | ||
| esophagogastric junction | Q66504896 | ||
| antineoplastic combined chemotherapy protocols | Q66764603 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 3464-3474 | |
| P577 | publication date | 2016-10-24 | |
| 2016-12-01 | |||
| P1433 | published in | Cancer Medicine | Q27724564 |
| P1476 | title | Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma | |
| P478 | volume | 5 |
| Q33775283 | Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma | cites work | P2860 |
Search more.